Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
229.21
-1.84 (-0.80%)
Apr 23, 2026, 11:51 AM EDT - Market open
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$711,121
Profits / Employee
-$225,181
Market Cap
14.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 4,700 |
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
ASND News
- 1 day ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire
- 3 days ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire
- 14 days ago - Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewsWire
- 15 days ago - New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia - GlobeNewsWire
- 16 days ago - Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - GlobeNewsWire
- 5 weeks ago - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 - GlobeNewsWire
- 5 weeks ago - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire